Carney D N
Mater Misericordiae Hospital, Dublin, Ireland.
Semin Oncol. 1995 Aug;22(4 Suppl 9):58-62.
Non-small cell lung cancer (NSCLC) represents almost three quarters of all cases of lung cancer. Most NSCLC patients present with either locally advanced inoperable disease, stage IV metastatic disease, or comorbid medical conditions that make them unsuitable for curative resection. Among NSCLC patients in the United States, overall 5-year survival rates range from 10% to 15%. Systemic chemotherapy has had minimal impact on prolonging survival or improving quality of life. Combination chemotherapy regimens containing cisplatin usually produce the best overall response rates. Combination chemotherapy in one study also has been shown to be more efficacious and less expensive than best supportive care. Newer cytotoxic agents, including vinorelbine, gemcitabine, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), docetaxel, and the camptothecins, have shown promise in the treatment of NSCLC. In combination with other effective agents (eg, cisplatin), response rates approaching 50% have been observed. A greater understanding of the biologic properties of lung cancer may help facilitate early detection and chemoprevention in patients at risk.
非小细胞肺癌（NSCLC）占所有肺癌病例的近四分之三。大多数NSCLC患者表现为局部晚期无法手术的疾病、IV期转移性疾病或合并有其他疾病，使其不适合进行根治性切除。在美国的NSCLC患者中，总体5年生存率在10%至15%之间。全身化疗对延长生存期或改善生活质量的影响微乎其微。含顺铂的联合化疗方案通常能产生最佳的总体缓解率。一项研究表明，联合化疗比最佳支持治疗更有效且成本更低。包括长春瑞滨、吉西他滨、紫杉醇（泰素；百时美施贵宝公司，新泽西州普林斯顿）、多西他赛和喜树碱在内的新型细胞毒性药物在NSCLC治疗中显示出了前景。与其他有效药物（如顺铂）联合使用时，观察到缓解率接近50%。对肺癌生物学特性的更深入了解可能有助于促进对高危患者的早期检测和化学预防。
